Isabelle Danner-Boucher
Overview
Explore the profile of Isabelle Danner-Boucher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burgel P, Sermet-Gaudelus I, Girodon E, Durieu I, Houdouin V, Audousset C, et al.
Lancet Respir Med
. 2024 Aug;
12(11):888-900.
PMID: 39151434
Background: Elexacaftor-tezacaftor-ivacaftor has been approved in Europe for people with cystic fibrosis with at least one F508del CFTR variant. Additionally, it is approved by the US Food and Drug Administration...
2.
Ramel S, Gueganton L, Nowak E, Le Bihan J, Arnouat B, Belleguic C, et al.
J Cyst Fibros
. 2024 Apr;
23(4):647-652.
PMID: 38688746
Background: Sexual dysfunction (erectile dysfunction in males, sexual dissatisfaction, sexual interest/arousal disorders, and dyspareunia in females) has not been the subject of indepth research in people with cystic fibrosis (CF)....
3.
Burgel P, Paillasseur J, Durieu I, Reynaud-Gaubert M, Hamidfar R, Murris-Espin M, et al.
Ann Am Thorac Soc
. 2024 Apr;
21(7):1053-1064.
PMID: 38579175
Limited data exist on the safety and effectiveness of elexacaftor-tezacaftor-ivacaftor (ETI) in people with cystic fibrosis (pwCF) and advanced lung disease. To evaluate the effects of ETI in an unselected...
4.
Rakotoarisoa L, Weiss L, Lefebvre F, Porzio M, Renaud-Picard B, Ravoninjatovo B, et al.
J Diabetes Complications
. 2024 Mar;
38(4):108703.
PMID: 38430625
Background: Cystic fibrosis related diabetes (CFRD) is commonly associated with declining lung function and nutritional status. We aimed to evaluate the pulmonary impact of early glucose abnormalities by using 2-h...
5.
Hubeaux K, Gueganton L, Nowak E, Arnouat B, Belleguic C, Danner-Boucher I, et al.
J Cyst Fibros
. 2023 Oct;
23(3):579-586.
PMID: 37907384
Background: In cystic fibrosis (CF), coughing is associated with a risk of pelvic floor dysfunction. However, data on the prevalence of symptoms (stress urinary incontinence, bladder overactivity, dysuria, and faecal...
6.
Andrejak C, Priou P, Richaud-Thiriez B, Macey J, Montcouquiol S, Douvry B, et al.
Eur Respir J
. 2023 Feb;
61(5.
PMID: 36796836
Background: The European Medicines Agency has approved the cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination elexacaftor/tezacaftor/ivacaftor (ETI) for people with cystic fibrosis (CF) carrying at least one F508del variant....
7.
Delbove A, Senage T, Gazengel P, Tissot A, Lacoste P, Cellerin L, et al.
Ther Adv Respir Dis
. 2022 Jul;
16:17534666221110354.
PMID: 35894432
Background: Anastomotic complications are common after lung transplantation (1.4-33% of cases) and still associated with a high morbi-mortality. Methods: The current study is a monocenter retrospective analysis of symptomatic anastomotic...
8.
Corvol H, de Miranda S, Dehillotte C, Lemonnier L, Chiron R, Danner-Boucher I, et al.
Clin Infect Dis
. 2022 Apr;
75(12):2135-2144.
PMID: 35475917
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are closely monitored in people with cystic fibrosis (pwCF), especially severe cases. Previous studies used hospitalization rates as proxy for severity....
9.
Martin C, Reynaud-Gaubert M, Hamidfar R, Durieu I, Murris-Espin M, Danner-Boucher I, et al.
J Cyst Fibros
. 2022 Feb;
21(3):489-496.
PMID: 35123901
Background: Elexacaftor-tezacaftor-ivacaftor induces rapid clinical improvement in patients with cystic fibrosis (CF) and advanced pulmonary disease, often leading to suspend the indication for lung transplantation. Yet no long-term data is...
10.
Meijer L, Hery-Arnaud G, Leven C, Nowak E, Hillion S, Renaudineau Y, et al.
J Cyst Fibros
. 2021 Dec;
21(3):529-536.
PMID: 34961705
Background: The orally available kinase inhibitor R-roscovitine has undergone clinical trials against various cancers and is currently under clinical evaluation against Cushing disease and rheumatoid arthritis. Roscovitine displays biological properties...